HURA•benzinga•
TuHURA Biosciences Initiates Phase 1b/2a Study Of IFx-Hu2.0 As An Adjunctive Therapy To Keytruda In First Line Treatment For Metastatic Merkel Cell Carcinoma Of Unknown Primary Origin
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 5, 2025 by benzinga